Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic human umbilical cord blood haematopoietic progenitor cell therapy - StemCyte

Next Previous
Drug Profile

Allogeneic human umbilical cord blood haematopoietic progenitor cell therapy - StemCyte

Alternative Names: HPC-cord blood - StemCyte; RegeneCyte; REGENECYTE

Latest Information Update: 31 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator StemCyte
  • Class Haematopoietic stem cells therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Haematological disorders; Immunological disorders
  • Phase II Post acute COVID 19 syndrome

Most Recent Events

  • 23 Mar 2026 StemCyte initiates an expanded-access program for Post-acute-COVID-19-syndrome in USA (IV, Infusion) (NCT07332338)
  • 26 Jan 2026 The US Food and Drug Administration (US FDA) clears an Expanded Access (EA) programme for RegeneCyte for the treatment of post acute COVID-19 syndrome
  • 23 Sep 2025 StemCyte International plans a phase III trial for Post acute COVID-19 syndrome in unknown location in March 2026 (NCT07184385)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top